Korean startup Lynk Solutec, which has developed a medical coating technology called “Lynk Coating” to address side effects such as infections, inflammation, and thrombosis during surgeries, has secured a pre-Series A investment from POSTECH Holdings.

Lynk Solutec was founded by CEO Jungmok Seo, who holds a Ph.D. in Electrical and Electronic Engineering from Yonsei University and completed a Postdoctoral Fellowship at Harvard Medical School in Ali Khademhosseini’s lab. Currently, he serves as an associate professor in Electrical and Electronic Engineering at Yonsei University. The company specializes in developing anti-adhesion coating technology for medical devices to prevent side effects. The Lynk Coating solution is designed to prevent the adhesion of infectious agents like blood and bacteria on various medical device surfaces, effectively inhibiting thrombosis formation and addressing pre- and post-surgical complications.

Lynk Solutec has secured a core patent for its nano oil-film coating technology, inspired by the lubricated surface of the pitcher plant. This proprietary technology allows reapplication without additional cleaning when performance deteriorates, integrating the cleaning and recoating process. This innovation not only reduces overall surgical time but also enhances operational efficiency. The company’s technological excellence was recognized with Innovation Awards in the Human Security and Digital Health categories at CES 2024, and it also won the ‘R&D Innovation Grand Prize’ in 2024.

Jae Hyun Kim, an investment director at POSTECH Holdings, stated, “Lynk Solutec’s technology can be applied to various forms and materials of medical devices. The company has demonstrated significant technical validation, particularly through the development of coated endoscopic caps and coating solutions. Moreover, Lynk Solutec’s technology is not limited to endoscopy but can also be applied to stents, catheters, and silicone tubes for lacrimal duct insertion, suggesting significant growth potential across various medical sectors.”

Jungmok Seo, CEO of Lynk Solutec, commented, “With this investment from POSTECH Holdings, we expect significant support in launching our first product and developing subsequent products in the ophthalmology and urology fields”